Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis

作     者：Qiu Wei Hua Lin Rong-Guo Wei Nian Chen Fan He Dong-Hua Zou Jin-Ru Wei 

作者机构：Department of Environmental and Global HealthCollege of Public Clinical Medical Laboratory CenterThe Fifth Affiliated Hospital of Guangxi Medical University89 Qixing RoadNanning 530022GuangxiChina 不详 

出 版 物：《Infectious Diseases of Poverty》 (贫困所致传染病（英文）)

年 卷 期：2021年第10卷第3期

页      面：95-95页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：Guangxi medical and health key discipline construction project High-Level Medical Expert Training Program of Guangxi “139” Plan Funding, (G201903049) Project of Nanning Scientific Research and Technology Development Plan, (20183040-4) Project of Qingxiu District of Nanning Scientific Research and Technology Development Plan, (2019038, 2020059) 

主　　题：Tocilizumab COVID-19 IL-6 Cytokine storm 

摘      要：Background:Coronavirus disease 2019(COVID-19)has killed over 2.5 million people worldwide,but effective care and therapy have yet to be *** conducted this analysis to better understand tocilizumab treatment for COVID-19 *** text:We searched major databases for manuscripts reporting the effects of tocilizumab on COVID-19 patients.A total of 25 publications were analyzed with Revman 5.3 and R for the *** better clinical outcomes were found in the tocilizumab treatment group when compared to the standard care group[odds ratio(OR)=0.70,95%confidential interval(CI):0.54-0.90,0.007].Tocilizumab treatment showed a stronger correlation with good prognosis among COVID-19 patients that needed mechanical ventilation(OR=0.59,95%CI:0.37-0.93,P=0.02).